The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge

The multidrug resistance protein 4 (Mrp4) is an ATP-binding cassette transporter that is capable of exporting the second messenger cAMP from cells, a process that might regulate cAMP-mediated anti-inflammatory processes. However, using LPS- or cigarette smoke (CS)-inflammation models, we found that...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 8; no. 4; p. e61193
Main Authors: Schymeinsky, Jürgen, Mayer, Hannah, Tomsic, Christopher, Tilp, Cornelia, Schuetz, John D, Cui, Yunhai, Wollin, Lutz, Gantner, Florian, Erb, Klaus J
Format: Journal Article
Language:English
Published: United States Public Library of Science 22-04-2013
Public Library of Science (PLoS)
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The multidrug resistance protein 4 (Mrp4) is an ATP-binding cassette transporter that is capable of exporting the second messenger cAMP from cells, a process that might regulate cAMP-mediated anti-inflammatory processes. However, using LPS- or cigarette smoke (CS)-inflammation models, we found that neutrophil numbers in the bronchoalveolar lavage fluid (BALF) were similar in Mrp4(-/-) and Mrp4(+/+) mice treated with LPS or CS. Similarly, neutrophil numbers were not reduced in the BALF of LPS-challenged wt mice after treatment with 10 or 30 mg/kg of the Mrp1/4 inhibitor MK571. The absence of Mrp4 also had no impact on the influx of eosinophils or IL-4 and IL-5 levels in the BALF after OVA airway challenge in mice sensitized with OVA/alum. LPS-induced cytokine release in whole blood ex vivo was also not affected by the absence of Mrp4. These data clearly suggest that Mrp4 deficiency alone is not sufficient to reduce inflammatory processes in vivo. We hypothesized that in combination with PDE4 inhibitors, used at suboptimal concentrations, the anti-inflammatory effect would be more pronounced. However, LPS-induced neutrophil recruitment into the lung was no different between Mrp4(-/-) and Mrp4(+/+) mice treated with 3 mg/kg Roflumilast. Finally, the single and combined administration of 10 and 30 mg/kg MK571 and the specific breast cancer resistance protein (BCRP) inhibitor KO143 showed no reduction of LPS-induced TNFα release into the BALF compared to vehicle treated control animals. Similarly, LPS-induced TNFα release in murine whole blood of Mrp4(+/+) or Mrp4(-/-) mice was not reduced by KO143 (1, 10 µM). Thus, BCRP seems not to be able to compensate for the absence or inhibition of Mrp4 in the used models. Taken together, our data suggest that Mrp4 is not essential for the recruitment of neutrophils into the lung after LPS or CS exposure or of eosinophils after allergen exposure.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors have the following interests. JS, HM, C. Tomsic, C. Tilp, YC, LW, FG and KJE are employees of Boehringer-Ingelheim Pharma GmbH & Co KG which is a research-based pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines for humans and animals. Boehringer-Ingelheim Pharma GmbH & Co KG provided funding for the experiments. Roflumilast was resynthesized at Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. A semi-automatic cigarette lighter and smoke generator with an electronic timer was used to control the CS exposure (Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany). There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Revised and approved the manuscript: JDS YC FG LW. Conceived and designed the experiments: JS YC LW FG KJE. Performed the experiments: JS HM C. Tomsic C. Tilp. Analyzed the data: JS HM C. Tomsic YC LW KJE C. Tilp. Contributed reagents/materials/analysis tools: JDS. Wrote the paper: JS KJE.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0061193